Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous and hemodialysis use. It is employed to prevent deep‑vein thrombosis, treat pulmonary embolism and provide anticoagulation during renal replacement therapy in adult patients.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen, a low molecular weight heparin, is used in clinical situations that require inhibition of clot formation. - Deep vein thrombosis (DVT) prevention: reduces the risk of clot formation in at‑risk surgical or immobilised patients. - Pulmonary embolism (PE) treatment: helps dissolve existing clots and prevents new emboli. - Anticoagulation during hemodialysis: maintains circuit patency by limiting clotting during the procedure.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects: - Injection site pain or erythema: localized discomfort at the administration site. - Bruising or hematoma: minor bleeding under the skin. - Mild gastrointestinal upset: nausea or dyspepsia. - Transient elevation of liver enzymes: mild, reversible changes. - Minor platelet count reduction: mild thrombocytopenia without clinical sequelae.

Serious or Rare Side Effects: - Major bleeding: gastrointestinal, intracranial or surgical site hemorrhage. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation. - Spinal or epidural hematoma: risk after neuraxial procedures. - Allergic reactions: urticaria, angioedema or anaphylaxis. - Elevated liver transaminases: significant hepatic injury. - Disseminated intravascular coagulation (DIC): uncontrolled clotting and bleeding.

Before initiating Ledraxen, clinicians should assess individual risk factors and monitor patients closely. - Bleeding risk assessment: evaluate history of hemorrhage, active ulcers or recent surgery. - Renal function monitoring: dose adjustment may be required in severe impairment. - Concomitant anticoagulant use: avoid combining with other blood thinners unless medically justified. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin can interact with several drug classes, altering its anticoagulant effect.

Major Interactions (Avoid): - Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): increased hemorrhage potential. - Thrombolytic therapy (e.g., alteplase): synergistic effect on clot dissolution. - Neuraxial anesthesia or spinal puncture: heightened risk of epidural hematoma.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate bleeding. - Certain antibiotics (e.g., quinolones, macrolides): can affect platelet function. - ACE inhibitors or diuretics: monitor renal function and electrolytes. - Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding tendency.